title: Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
abstract: Hypoxia-inducible factor-1α (HIF-1α) and signal transducer and activator of transcription 3 (STAT3) are transcription factors and are activated in response to hypoxia. Both HIF-1α and STAT3 regulate various aspects of cancer biology such as cell survival, proliferation, angiogenesis etc. and are constitutively expressed in a wide range of human cancers. In the last decade, over expression of HIF-1α and STAT3 has been demonstrated in many common human cancers, thereby emerging as highly compelling anticancer targets for drug discovery. We herein report the design and synthesis of new imidazopyridine based potent dual inhibitors of HIF-1α and STAT3 pathways. The lead compound of this series P3971 has been identified as a potent inhibitor of HIF-1α (200 nM) and STAT3 (350 nM) with significant antiproliferative activity against various cancer cell lines. Moreover, P3971 was also found to be orally efficacious in HCT116 (colon cancer) and H460 (lung cancer) xenograft mice models.
authors.affiliation: Department of Medicinal Chemistry, Piramal Life Sciences Ltd. Mumbai, India- 400063. sanjay.kumar@piramal.com.
authors.forename: Pallavi
authors.initials: P
authors.lastname: Godse
authors.forename: Pramod
authors.initials: P
authors.lastname: Kumar
authors.forename: Nilambari
authors.initials: N
authors.lastname: Yewalkar
authors.forename: Vijaykumar
authors.initials: V
authors.lastname: Deore
authors.forename: Manoj
authors.initials: M
authors.lastname: Lohar
authors.forename: Ramswaroop
authors.initials: R
authors.lastname: Mundada
authors.forename: Amol
authors.initials: A
authors.lastname: Padgaonkar
authors.forename: Sonal
authors.initials: S
authors.lastname: Manohar
authors.forename: Asavari
authors.initials: A
authors.lastname: Joshi
authors.forename: Dimple
authors.initials: D
authors.lastname: Bhatia
authors.forename: Nikesh
authors.initials: N
authors.lastname: Desai
authors.forename: Anagha
authors.initials: A
authors.lastname: Damre
authors.forename: Mandar
authors.initials: M
authors.lastname: Bhonde
authors.forename: Kalpana
authors.initials: K
authors.lastname: Joshi
authors.forename: Rajiv
authors.initials: R
authors.lastname: Sharma
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kumar
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007093:Imidazoles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D016513:Mice, SCID; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D050796:STAT3 Transcription Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: C000593995:5-fluoro-N,2-dimethyl-N'-((6-(pyridin-3-yl)imidazo(1,2-a)pyridin-3-yl)methylene)benzenesulfonohydrazide; D000970:Antineoplastic Agents; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007093:Imidazoles; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; D013449:Sulfonamides